JP2023553210A - がんの処置のための併用療法 - Google Patents

がんの処置のための併用療法 Download PDF

Info

Publication number
JP2023553210A
JP2023553210A JP2023559962A JP2023559962A JP2023553210A JP 2023553210 A JP2023553210 A JP 2023553210A JP 2023559962 A JP2023559962 A JP 2023559962A JP 2023559962 A JP2023559962 A JP 2023559962A JP 2023553210 A JP2023553210 A JP 2023553210A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553210A5 (enExample
Inventor
マリゴウダ，シヴァクマー，バドラヴァティ
アー，マドゥカラ
パンデイ，プラシャント，クマー
ボレディー，スリニヴァス，レディー
ネアー，プラディップ
Original Assignee
バイカラ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイカラ セラピューティクス インコーポレイテッド filed Critical バイカラ セラピューティクス インコーポレイテッド
Publication of JP2023553210A publication Critical patent/JP2023553210A/ja
Publication of JP2023553210A5 publication Critical patent/JP2023553210A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2023559962A 2020-12-15 2021-12-15 がんの処置のための併用療法 Pending JP2023553210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011054571 2020-12-15
IN202011054571 2020-12-15
PCT/US2021/010067 WO2022132202A1 (en) 2020-12-15 2021-12-15 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023553210A true JP2023553210A (ja) 2023-12-20
JP2023553210A5 JP2023553210A5 (enExample) 2024-12-24

Family

ID=82058750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559962A Pending JP2023553210A (ja) 2020-12-15 2021-12-15 がんの処置のための併用療法

Country Status (7)

Country Link
US (1) US20240082394A1 (enExample)
EP (1) EP4263584A4 (enExample)
JP (1) JP2023553210A (enExample)
CN (1) CN116940592A (enExample)
AU (1) AU2021400979A1 (enExample)
CA (1) CA3202374A1 (enExample)
WO (1) WO2022132202A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417012A (zh) * 2022-08-19 2024-05-01 美商旗艦先鋒創新公司 包含myc調節劑及檢查點抑制劑之組合療法
WO2024167880A1 (en) * 2023-02-06 2024-08-15 Bicara Therapeutics Inc. Combination therapy and related methods
WO2024189544A1 (en) * 2023-03-13 2024-09-19 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190169621A1 (en) * 2012-04-30 2019-06-06 Biocon Limited Targeted/immunomodulatory fusion proteins in combination with additional therapeutic agents and methods for making same
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
JP2019526613A (ja) * 2016-09-26 2019-09-19 イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ 癌のための併用療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
CA3253628A1 (en) * 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2902830C (en) * 2013-03-12 2023-09-19 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190169621A1 (en) * 2012-04-30 2019-06-06 Biocon Limited Targeted/immunomodulatory fusion proteins in combination with additional therapeutic agents and methods for making same
JP2019526613A (ja) * 2016-09-26 2019-09-19 イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ 癌のための併用療法
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ID NCT04429542, VIEWING V4 (2020-09-14) [オンライン ], JPN6025053337, 14 September 2020 (2020-09-14), ISSN: 0005765977 *
INT J RADIAT ONCOL, vol. Vol. 106, No. 5, Suppl., JPN6025053335, 1 April 2020 (2020-04-01), pages 1121 - 1122, ISSN: 0005765979 *
ONCO TARGETS THER, vol. 12, JPN6025053336, 2019, pages 9527 - 9538, ISSN: 0005765978 *

Also Published As

Publication number Publication date
US20240082394A1 (en) 2024-03-14
CA3202374A1 (en) 2022-06-23
EP4263584A4 (en) 2024-11-27
WO2022132202A1 (en) 2022-06-23
CN116940592A (zh) 2023-10-24
EP4263584A1 (en) 2023-10-25
AU2021400979A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US10532096B2 (en) Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
JP6383419B2 (ja) 腫瘍免疫のモジュレーション
JP5068270B2 (ja) 癌を処置するためのｉｌ−１７アンタゴニスト抗体
JP6385277B2 (ja) 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
CN101102791B (zh) 抗血管内皮生长因子受体-1的抗体
JP2021527714A (ja) 抗ｐｄ−１抗体及びその使用
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2017538660A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
CN114502595B (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
EP4292611A1 (en) Anti-cd112r antibody and use thereof
KR20230066040A (ko) 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
US20250092127A1 (en) IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer
US20190270802A1 (en) Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
JP2023553210A (ja) がんの処置のための併用療法
KR20230066392A (ko) 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
CN114790241A (zh) 抗tigit抗体及其应用
CN116710486A (zh) 用于治疗癌症的多特异性抗体
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
HK40097873A (zh) 用於治疗癌症的组合疗法
BR122024026022A2 (pt) Uso de um anticorpo, ou fragmento funcional ou variante funcional do mesmo, e de uma proteína de fusão para o tratamento de câncer
TW202235444A (zh) 結合人類ＴＧＦβ和ＰＤ－Ｌ１的雙功能分子及其應用
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
HK40095625A (zh) 用於治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260330